FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues
NCT ID: NCT05698082
Last Updated: 2023-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
120 participants
INTERVENTIONAL
2020-12-01
2025-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
NCT05575635
Molecular Study and Precision Medicine for Colorectal Cancer
NCT05883683
The Impact of Immune Cell Changes During the Perioperative Period on the Prognosis of Patients With Colorectal Cancer
NCT05015296
Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer
NCT06255379
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer
NCT05635149
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test group-stained by FOS antibody
Sixty colorectal cancer tissue sections were included. The tissue was cut to 5 μm thick and placed on a glass slide for staining. Endogenous peroxidase activity was inhibited and blocked by deparaffin, rehydration, and treatment with 5% bovine serum albumin for 30 min at 37 ° C. The treated sections were incubated with anti-FOS (promab 30360) overnight at 4 ° C and washed three times with PBS. After that, it was required to incubate with secondary anti-peroxidation sunflower for 30 min at 37 ° C. After washing three times with PBS, the images were developed in diamine benzidine and micrographs were obtained under a light microscope.
Immunohistochemical staining with anti-FOS
The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immunohistochemical staining with anti-FOS
The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
xiaoliang Huang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
xiaoliang Huang
clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY-2020-305
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.